Previous 10 | Next 10 |
LAUSANNE, Switzerland, May 15, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision Medicine in neurodegenerative diseases, today announced financial results for the first quarter ...
LAUSANNE, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will present at the H.C. Wainwright Global Life Sciences Confer...
AC Immune SA (NASDAQ: ACIU ) presents new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinson’s disease-brain derived alpha-synuclein (a-syn), potentially capable of accurately detecting and monitoring progression...
Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synuclein Potentially first diagnostic for detecting and monitoring Parkinson’s disease Further reinforces productivity of Morphomer TM drug discovery platform LAUS...
Next generation Tau PET-Tracer, 18 F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP New data further support 18 F-PI-2620’s potential as a new PET Tracer for progressive supranuclear palsy (PSP) detection LAUSANNE, Switzerland,...
Editor's note: Seeking Alpha is proud to welcome Nicholas Pugliese as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Last we...
Gainers: Seelos Therapeutics (NASDAQ: SEEL ) +40% . Hibbett Sports (NASDAQ: HIBB ) +23% . Bio-Path Holdings (NASDAQ: BPTH ) +18% . Immutep (NASDAQ: IMMP ) +17% . CounterPath (NASDAQ: CPAH ) +12% . Destination Maternity (NASDAQ: DEST ) +11% . Netshoes (NYSE: NETS ) +11% . AC Im...
AC Immune (NASDAQ: ACIU ): FY Non-GAAP EPS of -CHF0.76; GAAP EPS of -CHD0.82. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates Morphomer TM platform Initiation of second Phase 2 trial of Tau antibody by partner Genentech Multiple other products progressing, key appointments made to executive team ...
LAUSANNE, Switzerland, March 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will provide oral presentations addressing the progress of four...
News, Short Squeeze, Breakout and More Instantly...
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner ...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...